Prevention of Visual Field Defect Progression With Angiotensin-Converting Enzyme Inhibitor in Eyes With Normal-tension Glaucoma - 19/08/11
, Tetsuya Baba, MD a, Takashi Fujimura, MD b, Fumio Shiraga, MD a
Inquiries to Kazuyuki Hirooka, MD, Department of Ophthalmology, Kagawa University Faculty of Medicine, 1750-1 Ikenobe, Miki, Kagawa 761-793 JapanRésumé |
Purpose |
To report the effect of angiotensin-converting enzyme (ACE) inhibitor on visual field changes in normal-tension glaucoma (NTG).
Design |
Retrospective observational case series.
Methods |
We retrospectively reviewed a total of 38 patients with NTG. Control subjects had no previous history of hypertension. NTG hypertension patients were divided into two groups, those receiving ACE inhibitor and those receiving other antihypertensive drug treatments. HfaFiles 5, an analytical program for the Humphrey Field Analyzer, was used to calculate the slope for the mean deviation (MD) change per year.
Results |
In the ACE inhibitor-treated group, the mean MD change per year was 0.48 ± 0.19 dB, in control subjects was −0.38 ± 0.23 dB, and in the other antihypertensive drug-treated group was −0.50 ± 0.39 dB.
Conclusions |
Although the present study is retrospective and the sample size is small, ACE inhibitor might have a favorable effect on the visual field in patients with NTG in this small study.
Le texte complet de cet article est disponible en PDF.
Vol 142 - N° 3
P. 523-525 - septembre 2006 Retour au numéro
Article précédent
- Disappearance of Myelinated Retinal Nerve Fibers After Pars Plana Vitrectomy
- Adrienne J. Williams, Sharon Fekrat
- Phacoemulsification Associated Corneal Damage Evaluated by Corneal Volume
- Hisaharu Suzuki, Hiroshi Takahashi, Junko Hori, Miki Hiraoka, Tsutomu Igarashi, Toshihiko Shiwa
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?